NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

Shelton, Connecticut Thursday, July 17, 2025, 18:00 Hrs [IST] ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage pioneer in host-mimetic nanomedicine, affirmed its preparedness to address the continued ...

Late last year, NanoViricides was in the process of filing an Investigational New Drug application with the U.S. Food and Drug Administration for NV-HHV-101, its lead drug candidate for the ...

NanoViricides, Inc., a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program activities. Anil Diwan, the Company's President, and ...

NanoViricides, Inc., says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not ...

SHELTON, CT / ACCESSWIRE / May 26, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel ...

NanoViricides is preparing to file an IND and transition into a clinical-stage biotech. Once NV-HHV-101 is in the clinic, the company expects to advance their HSV-1 “cold sores” and of HSV-2 ...

SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel ...

Our research suggests that NanoViricides (NNVC) is unable to even attempt to create a coronavirus vaccine or treatment. On 1/24/20, NNVC sold 2.85M shares at $3 apiece, which is about 20% of the ...